IG
UTHR icon

ING Group’s United Therapeutics UTHR Stock Holding History

ING Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,800
Closed -$2.02M – 629
2024
Q1 		$2.02M Buy
8,800
+1,800
+26% +$406K 0.01% 446
2023
Q4 		$1.54M Buy
+7,000
New +$1.61M 0.01% 435
2019
Q3 		– Sell
-6,715
Closed -$524K – 745
2019
Q2 		$524K Buy
+6,715
New +$628K 0.01% 501
2018
Q4 		– Sell
-6,660
Closed -$852K – 831
2018
Q3 		$852K Buy
+6,660
New +$824K 0.01% 399
2016
Q1 		– Sell
-3,345
Closed -$524K – 681
2015
Q4 		$524K Buy
+3,345
New +$487K ﹤0.01% 565
2014
Q2 		– Sell
-42,396
Closed -$3.99M – 690
2014
Q1 		$3.99M Sell
42,396
-2,124
-5% -$217K 0.02% 400
2013
Q4 		$5.03M Sell
44,520
-3,266
-7% -$295K 0.03% 362
2013
Q3 		$3.77M Hold
47,786
– – 0.02% 417
2013
Q2 		$3.14M Buy
+47,786
New +$3.08M 0.02% 425

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ING Group's UTHR Position: Q2 2024 in Review

ING Group sold out of United Therapeutics (UTHR) in Q2 2024, closing a stake of 8,800 shares — an estimated $2.02M sold.

ING Group first reported a position in UTHR in Q2 2013 and held it in 9 quarters. The position peaked at $5.03M in Q4 2013. 566 funds tracked by Wall St. Rank hold UTHR as of Q2 2024.

  • ING Group reported no remaining United Therapeutics position as of Q2 2024 after selling out during the quarter.
  • ING Group sold 8,800 United Therapeutics shares in Q2 2024, an estimated $2.02M.
  • ING Group first reported a position in United Therapeutics in Q2 2013 and held it in 9 quarters.
  • ING Group's United Therapeutics position peaked at $5.03M in Q4 2013.
  • 566 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2024.

Based on ING Group's 13F filing for Q2 2024, filed 13 Aug 2024.